Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Common Stock (Narrative) (Details)

Common Stock (Narrative) (Details) (USD $)	0 Months Ended																																					1 Months Ended										0 Months Ended															0 Months Ended
Common Stock (Narrative) (Details) (USD $)	Dec. 10, 2012	Dec. 07, 2012	Dec. 04, 2012	Mar. 31, 2011	Mar. 28, 2011	Mar. 11, 2011	Feb. 28, 2011	Feb. 15, 2011	Jan. 19, 2011	Jun. 30, 2010	Apr. 20, 2010	Feb. 12, 2010	Oct. 23, 2009	Sep. 21, 2009	Sep. 04, 2009	Jun. 09, 2009	Jun. 05, 2009	Jun. 30, 2008	Jun. 02, 2008	May 30, 2008	Mar. 20, 2008	Dec. 27, 2007	Dec. 18, 2007	Sep. 27, 2007	Jul. 23, 2007	Apr. 18, 2007	Dec. 19, 2006	Nov. 09, 2006	Oct. 09, 2006	May 13, 2006	Apr. 12, 2006	Feb. 22, 2006	Dec. 27, 2005	Dec. 02, 2005	Aug. 08, 2005	Oct. 29, 2004	May 10, 2001	Oct. 31, 2011	Sep. 30, 2011	Dec. 31, 2010	Nov. 30, 2010	May 31, 2010	Apr. 30, 2010	Mar. 31, 2010	Jul. 31, 2003	Mar. 31, 2013	Dec. 31, 2012	Aug. 10, 2001 Director [Member]	Aug. 10, 2001 Rexgene [Member]	Oct. 10, 2001 Individual Investors [Member]	Aug. 10, 2001 Individual Investors [Member]	Oct. 10, 2001 Chong Kun Dang Pharmaceutical Corp [Member]	Oct. 10, 2001 Chong Kun Dang Pharmaceutical Corp Issuance Two [Member]	Aug. 20, 2003 KT&G Corporation [Member]	May 13, 2005 Corporate Road Show Com Inc. [Member]	Oct. 03, 2005 W. Rosenstadt And Steve Sanders [Member]	Feb. 12, 2010 Second Issuance [Member]	Oct. 23, 2009 Second Issuance [Member]	Jun. 05, 2009 Series I Warrants [Member]	Jun. 05, 2009 Series II Warrants [Member]	Jun. 05, 2009 Series III Warrants [Member]	Mar. 31, 2011 Warrants To Institutional Investors [Member]	Dec. 04, 2012 Overallotment shares available [Member]	Dec. 04, 2012 Overallotment warrants available [Member]	Dec. 10, 2012 Overallotment shares exercised [Member]	Dec. 04, 2012 Overallotment shares exercised [Member]	Dec. 10, 2012 Overallotment warrants exercised [Member]	Dec. 04, 2012 Overallotment warrants exercised [Member]
Shares issued		2,083,333	19,130,435	8,333,333					2,334,515	6,666,667		300,000	6,072,383	3,102,837			2,857,143				642,858		4,857,159							3,850,000				650,000	4,175,000		3,600,000											1,208,332	958,334	400,000	360,000	400,000	200,000	500,000	500,000	7,000	200,000								2,000,000
Value of shares issued		$ 750,000							$ 3,950,000					$ 3,500,000																							$ 1											$ 1,450,000	$ 550,000	$ 479,991	$ 1,080,000	$ 479,991	$ 479,985	$ 2,000,000		$ 21,877
Shares transferred to officers and directors																																														800,000
Shares transferred to a voting trust																																													1,268,332
Value of exercised of stock options						12,000	6,000				86,000				3,600			12,000	12,000	7,200		18,000		15,600	12,000	14,400	6,000	1,800	2,400		3,409	1,200	9,600			1,800		19,200	22,040					21,240
Shares issued for options exercised						50,000	25,000				107,500				15,000			10,000	50,000	30,000		75,000		19,500	15,000	18,000	25,000	7,500	10,000		14,205	5,000	40,000			1,500		80,000	28,000					48,000																						869,565
Pre-reverse stock split shares																																																							289,780,000
Post-reverse stock split shares																																																							2,897,802
Issuance price per share		$ 0.36		$ 1.20					$ 1.69	$ 1.50			$ 0.82	$ 1.13		$ 1.05	$ 1.05				$ 1.40		$ 1.40							$ 1.00				$ 2.00	$ 2.00																							$ 0.82	$ 1.05	$ 1.25	$ 1.50
Cash paid in exchange for legal services	814,338																																																							7,500
Convertable note principal amount																														3,850,000				1,300,000
Purchase of treasury stock																															28,410															28,410	28,410
Proceeds from issuance	7,260,000	750,000	7,260,000	10,000,000					3,926,397	10,000,000			5,000,000	3,371,340			3,000,000				900,001		6,800,023
Exercise price at future date				$ 1.50						$ 1.90			$ 1.00								$ 1.80		$ 1.80
Private placement closing costs	977,434																						139,675
Number of warrants, Issued			10,521,739	3,333,333						2,000,000			2,125,334			862,246							107,144																																			569,502	2,222,222	1,866,666	1,555,555		2,869,565				1,100,000
Proceeds allocated to financing expense	332,108			97,667						180,080			101,693				122,257						138,326
Issuance cost incurred	645,326	63,658		706,124					23,603	681,773			351,928	128,659			289,090
Fair value	163,096		13,691,643							1,800,800						422,300																														2,473,163	2,842,065											476,200				2,826,666
Cash paid for warrants exercised					$ 102,857			$ 215,104																																			$ 1,966,375	$ 1,297,001
Shares issued for warrants exercised			0.55		124,917			209,042																																126,195	247,491	547,674	1,595,825	1,197,001																				1,578,261
Number of warrants, Exercised																																								530,900	936,883	890,051																										478,261
Warrants issued included in closing costs	880,000			208,333						200,000			245,932				142,857
Stock Issued During Period, Shares Issued in Accordance to the anti-dilution provision																1,833,341																																										2,018,143
Share Price			$ 0.33
Stock Warrants, Exercise Price			$ 0.472